Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04860505 · ClinicalTrials.gov registry record · Phase 4
Combo-PEP: Multipurpose Prevention of Post-Exposure Prophylaxis Regimens
A Phase 4 study of Sexually Transmitted Diseases, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04860505: Completed Phase 4 study of Sexually Transmitted Diseases, sponsored by Emory University.
NCT04860505 is a Phase 4 study of Sexually Transmitted Diseases that has completed, run by Emory University. The registered enrollment target is 20 participants, below the 1,250-participant average among 35 other Sexually Transmitted Diseases trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04860505, a Phase 4 study of Sexually Transmitted Diseases, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will determine tissue pharmacology of a single dose of doxycycline for sexually transmitted infection (STI) Post-exposure Prophylaxis (PEP).
Primary Outcome
Doxycycline concentration in tissue from a rectal biopsy was measured. Rectal biopsies were obtained from men. Women had the option to provide a rectal tissue sample.
Conditions Studied
Interventions
- DRUG Doxycycline
- DRUG Biktarvy
Study Locations (1)
Georgia
- Hope Clinic - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-05-20 |
| Est. Completion | 2022-05-09 |
| Phase | Phase 4 |
What the finished NCT04860505 record still lists
NCT04860505 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,250-participant average among 35 other Sexually Transmitted Diseases trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Sexually Transmitted Diseases appearing as the primary indexed condition, and to 2 interventions - of which Doxycycline is the first listed.
NCT04860505 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT04860505 about?
NCT04860505 is a clinical study titled "Combo-PEP: Multipurpose Prevention of Post-Exposure Prophylaxis Regimens". The study will determine tissue pharmacology of a single dose of doxycycline for sexually transmitted infection (STI) Post-exposure Prophylaxis (PEP).
What is the current status of trial NCT04860505?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2021-05-20. Estimated completion is 2022-05-09.
What conditions does trial NCT04860505 study?
This clinical trial studies the following conditions: Sexually Transmitted Diseases.
What interventions are being tested in trial NCT04860505?
The interventions under investigation include: Doxycycline (DRUG), Biktarvy (DRUG).
Who is sponsoring clinical trial NCT04860505?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04860505 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sexually Transmitted Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04860505's enrollment target sits among peer trials
20 35th of 35 higher than 1 of 35 other Sexually Transmitted Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sexually Transmitted Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mesalamine to Reduce T Cell Activation in HIV Infection
COMPLETED · Phase 4
-
Effectiveness of Integrating Prenatal Care in Reducing HIV/STDs Among Young Pregnant Women
COMPLETED · Phase 4
-
Rigorous Evaluation of Yes and Know, a Fully Virtual Sexual Health and Well-Being Intervention for Youth
RECRUITING · NA
-
Evaluation of Parent Toolkit 2.0 (Morehouse Family Health Study)
RECRUITING · NA
-
Health Information Technology to Reduce Disparities in Adolescent Health Outcomes: A Pragmatic Trial
RECRUITING · NA
-
Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI